Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice

[1]  N. P. H. Lan,et al.  An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis , 2021, eLife.

[2]  G. Ioannou.  Epidemiology and risk-stratification of NAFLD-associated HCC. , 2021, Journal of hepatology.

[3]  G. Sulaiman,et al.  Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment , 2021, Pharmaceutics.

[4]  B. Finck,et al.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus , 2021, Nature Reviews Endocrinology.

[5]  K. Dou,et al.  Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. , 2021, Cell metabolism.

[6]  Z. Younossi,et al.  AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review. , 2020, Gastroenterology.

[7]  Y. Kubota,et al.  Tamoxifen-Activated CreERT Impairs Retinal Angiogenesis Independently of Gene Deletion , 2020, Circulation research.

[8]  S. Ikramuddin,et al.  Nonalcoholic Steatohepatitis: A Review. , 2020, JAMA.

[9]  Lan Xiao,et al.  Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory , 2020, Nature Neuroscience.

[10]  J. Chan,et al.  Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory , 2020, Nature Neuroscience.

[11]  Y. Ao,et al.  Foreign body responses in mouse central nervous system mimic natural wound responses and alter biomaterial functions , 2019, Nature Communications.

[12]  Li Lv,et al.  Interplay between α2-chimaerin and Rac1 activity determines dynamic maintenance of long-term memory , 2019, Nature Communications.

[13]  Alexander P. Yllanes,et al.  Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy , 2019, Breast Cancer Research and Treatment.

[14]  Mamie Yu,et al.  Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility , 2019, Cell.

[15]  A. Omar,et al.  Enhanced anti-mammary gland cancer activities of tamoxifen-loaded erythropoietin-coated drug delivery system , 2019, PloS one.

[16]  K. Unsicker,et al.  Selective Liver Estrogen Receptor α Modulation Prevents Steatosis, Diabetes, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatokine in Mice , 2019, Hepatology communications.

[17]  David Lumelsky,et al.  Tamoxifen improves glucose tolerance in a delivery, sex, and strain-dependent manner in mice , 2018, bioRxiv.

[18]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[19]  M. Dallak.  Acylated ghrelin induces but deacylated ghrelin prevents hepatic steatosis and insulin resistance in lean rats: Effects on DAG/ PKC/JNK pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  K. Dou,et al.  Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice , 2018, Hepatology.

[21]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[22]  T. Bihani,et al.  Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. , 2017, Pharmacology & therapeutics.

[23]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[24]  Hervé Guillou,et al.  Selective Activation of Estrogen Receptor α Activation Function-1 Is Sufficient to Prevent Obesity, Steatosis, and Insulin Resistance in Mouse. , 2017, The American journal of pathology.

[25]  Parth Patel,et al.  Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers. , 2016, European journal of pharmacology.

[26]  F. Mauvais-Jarvis,et al.  Effect of selective estrogen receptor modulators on metabolic homeostasis. , 2016, Biochimie.

[27]  N. Lane,et al.  Optimizing tamoxifen-inducible Cre/loxp system to reduce tamoxifen effect on bone turnover in long bones of young mice. , 2015, Bone.

[28]  H. Fine,et al.  A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas , 2015, Journal of Neuro-Oncology.

[29]  Jieli Lu,et al.  Hepatic estrogen receptor α improves hepatosteatosis through upregulation of small heterodimer partner. , 2015, Journal of hepatology.

[30]  Lingqiang Zhang,et al.  The Effect and Mechanism of Tamoxifen-Induced Hepatocyte Steatosis in Vitro , 2014, International journal of molecular sciences.

[31]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[32]  K. Tsuneyama,et al.  Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. , 2012, Toxicology and applied pharmacology.

[33]  K. Tsuneyama,et al.  Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. , 2012, The Journal of toxicological sciences.

[34]  G. Kong,et al.  Gene expression profiling of murine hepatic steatosis induced by tamoxifen. , 2010, Toxicology letters.

[35]  D. Vance,et al.  Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis , 2010, Hepatology.

[36]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  M. S. Ozers,et al.  Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-gamma using time-resolved fluorescence resonance energy transfer. , 2006, Analytical biochemistry.

[38]  C. Lelliott,et al.  Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Karen M. Speirs,et al.  Expert Review テリスロマイシン , 2005 .

[40]  U. Veronesi,et al.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial , 2005, BMJ : British Medical Journal.

[41]  Yoshikuni Yakabe,et al.  Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. , 2004, Toxicology.

[42]  G. Jacquemin.  [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[43]  T. Clarkson,et al.  Estrogen replacement therapy, atherosclerosis, and vascular function. , 2002, Cardiovascular research.

[44]  A. Franchitto,et al.  Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. , 2000, Gastroenterology.

[45]  A. Howell.  Tamoxifen versus the newer SERMs: what is the evidence? , 2000, Annals of Oncology.

[46]  Q. Cai,et al.  Tamoxifen-induced transient multifocal hepatic fatty infiltration , 2000, American Journal of Gastroenterology.

[47]  Y. Ogawa,et al.  Tamoxifen-induced fatty liver in patients with breast cancer , 1998, The Lancet.

[48]  J. Vonesch,et al.  Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P Chambon,et al.  Ligand-activated site-specific recombination in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Y. Horsmans,et al.  Tamoxifen-Induced Steatohepatitis , 1996, Annals of Internal Medicine.

[51]  J. Erban,et al.  Tamoxifen-Induced Steatohepatitis , 1995, Annals of Internal Medicine.

[52]  G. Hortobagyi,et al.  Use of tamoxifen for breast cancer: twenty-eight years later. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. Papac,et al.  Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen. , 1993, European journal of cancer.

[54]  E. Winer,et al.  High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. , 1992, Journal of the National Cancer Institute.

[55]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[56]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[57]  B. Edwards,et al.  Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. , 1983, Annals of internal medicine.